Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05973487
Other study ID # TSCAN-002
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date May 6, 2024
Est. completion date December 30, 2026

Study information

Verified date June 2024
Source TScan Therapeutics, Inc.
Contact Marlyane Motta, BS
Phone 857-399-9887
Email mmotta@tscan.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. This is a multi-center, non-randomized, multi-arm, open-label, basket study evaluating the safety and preliminary efficacy of single and repeat dose regimens of TCR'Ts as monotherapies and as T-Plex combinations after lymphodepleting chemotherapy in participants with locally advanced, metastatic solid tumors disease.


Description:

Participants will be screened in a separate screening study, TSCAN-003 (NCT05812027), to assess their HLA type, tumor-associated antigen (TAA) expression and loss of heterozygosity (LOH) status. The results of these tests will be used to determine initial eligibility in this study. Depending on the genetic type, participants will be assigned to one of the following study groups: Monotherapy: - COHORT A: TSC-204-A0201 targeting MAGE-A1 on HLA-A*02:01 - COHORT B: TSC-204-C0702 targeting MAGE-A1 on HLA-C*07:02 - COHORT C: TSC-200-A0201 targeting HPV16 E7 on HLA-A*02:01 - COHORT D: TSC-203-A0201 targeting PRAME on HLA-A*02:01 - COHORT E: TSC-204-A0101 targeting MAGE-A1 on HLA-A*01:01 - COHORT F: TSC-201-B0702 targeting MAGE-C2 on HLA-B*07:02 T-Plex Combination: - COHORT AB: TSC-204-A0201 + TSC-204-C0702 - COHORT AC: TSC-204-A0201 + TSC-200-A0201 - COHORT AD: TSC-204-A0201 + TSC-203-A0201 - COHORT AE: TSC-204-A0201 + TSC-204-A0101 - COHORT AF: TSC-204-A0201 + TSC-201-B0702 - COHORT BC: TSC-204-C0702 + TSC-200-A0201 - COHORT BD: TSC-204-C0702 + TSC-203-A0201 - COHORT BE: TSC-204-C0702 + TSC-204-A0101 - COHORT BF: TSC-204-C0702 + TSC-201-B0702 - COHORT CD: TSC-200-A0201 + TSC-203-A0201 - COHORT CE: TSC-200-A0201 + TSC-204-A0101 - COHORT CF: TSC-200-A0201 + TSC-201-B0702 - COHORT DE: TSC-203-A0201 + TSC-204-A0101 - COHORT DF: TSC-203-A0201 + TSC-201-B0702 - COHORT EF: TSC-204-A0101 + TSC-201-B0702 Participants will undergo leukapheresis to collect cells to manufacture the TCR-T products. They will then undergo lymphodepletion and receive one or two doses of the TCR-T cell therapy product as a monotherapy or part of a combination of TCR-Ts (referred to as T-Plex combinations in this study).


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 30, 2026
Est. primary completion date December 30, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Must be at least 18 years. 2. Locally advanced (unresectable) or metastatic solid tumor for which there are no available curative treatment options, after failure of the standard of care systemic therapies for that particular indication. 3. Solid tumors, including but not limited to non-nasopharyngeal head and neck cancer, non-small cell lung cancer, cutaneous melanoma, cervical cancer, ovarian cancer, anal cancer and genital cancers. Other tumor types may be permitted if approved by TScan. 4. Participants must express one of the following HLA types, as assessed by a qualified genomics assay in screening study TSCAN-003: HLA-B*07:02 HLA-A*01:01 HLA-C*07:02 HLA-A*02:01 5. Tumor must express one or more of the following: MAGE-A1, MAGE-C2, PRAME and HPV16-E7 assessed in the last 8 months in screening study TSCAN-003 (NCT05812027). 6. Eastern Cooperative Oncology Group (ECOG) Performance status 0-1 at screening. 7. Participants must be able to understand and be willing to give informed consent; decision-impaired adults may consent with their legally authorized representative. 8. At least 1 measurable lesion per modified Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. 9. Adequate bone marrow and organ function. Exclusion Criteria: 1. Medical or psychological conditions that would make the participant unsuitable candidate for cell therapy at the discretion of the PI. 2. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, cardiac arrhythmia requiring antiarrhythmic or procedure, or other clinically significant cardiac disease within 12 months of enrollment 3. History of stroke or transient ischemic attack (TIA) within 12 months of enrollment 4. Systemic corticosteroid therapy >10 mg of prednisone daily or equivalent within 7 days of enrollment 5. History of severe hypersensitivity to fludarabine or cyclophosphamide or study product excipients including human serum albumin, Cryostor (DMSO or Dextran 40), or Plasma-Lyte. 6. Untreated or symptomatic central nervous system (CNS) metastases or cytology proven carcinomatous meningitis. 7. Concurrent receipt of another anti-cancer therapy. 8. Presence of fungal, bacterial, viral, or other infection requiring anti-microbials for management. 9. Tumors that have HLA LOH using a central lab clinical trial assay of HLAs addressed by the monotherapy and/or T-Plex combination TCR-Ts in the protocol and have no available TCR-T options for intact HLAs in the participant's tumor. 10. Participants who regularly require supplemental oxygen.

Study Design


Related Conditions & MeSH terms

  • Adenocarcinoma
  • Carcinoma
  • Carcinoma, Adenosquamous
  • Carcinoma, Squamous Cell
  • Cervical Cancer
  • Head and Neck Cancer
  • HPV - Anogenital Human Papilloma Virus Infection
  • HPV Positive Oropharyngeal Squamous Cell Carcinoma
  • HPV-Related Anal Squamous Cell Carcinoma
  • HPV-Related Carcinoma
  • HPV-Related Cervical Carcinoma
  • HPV-Related Malignancy
  • HPV-Related Penile Squamous Cell Carcinoma
  • HPV-Related Squamous Cell Carcinoma
  • HPV-Related Vulvar Squamous Cell Carcinoma
  • Melanoma
  • Non-small Cell Carcinoma
  • Ovarian Cancer
  • Papilloma
  • Papillomavirus Infections
  • Squamous Cell Carcinoma of Head and Neck

Intervention

Biological:
TSC-204-A0201
Escalating doses of TSC-204-A0201 as a monotherapy
TSC-204-C0702
Escalating doses of TSC-204-C0702 as a monotherapy
TSC-200-A0201
Escalating doses of TSC-200-A0201 as a monotherapy
TSC-204-A0201 + TSC-204-C0702
Escalating doses of TSC-204-A0201 in combination with TSC-204-C0702
TSC-204-A0201 + TSC-200-A0201
Escalating doses of TSC-204-A0201 in combination with TSC-200-A0201
TSC-204-C0702 + TSC-200-A0201
Escalating doses of TSC-204-C0702 in combination with TSC-200-A0201
TSC-204-A0201 + TSC-203-A0201
Escalating doses of TSC-204-A0201 in combination with TSC-203-A0201
TSC-204-C0702 + TSC-203-A0201
Escalating doses of TSC-204-C0702 in combination with TSC-203-A0201
TSC-200-A0201 + TSC-203-A0201
Escalating doses of TSC-200-A0201 in combination with TSC-203-A0201
TSC-203-A0201
Escalating doses of TSC-203-A0201 as a monotherapy
TSC-204-A0101
Escalating doses of TSC-204-A0101 as a monotherapy
TSC-201-B0702
Escalating doses of TSC-201-B0702 as a monotherapy
TSC-204-A0201 + TSC-204-A0101
Escalating doses of TSC-204-A0201 in combination with TSC-204-A0101
TSC-204-A0201 + TSC-201-B0702
Escalating doses of TSC-204-A0201 in combination with TSC-201-B0702
TSC-204-C0702 + TSC-204-A0101
Escalating doses of TSC-204-C0702 in combination with TSC-204-A0101
TSC-204-C0702 + TSC-201-B0702
Escalating doses of TSC-204-C0702 in combination with TSC-201-B0702
TSC-200-A0201 + TSC-204-A0101
Escalating doses of TSC-200-A0201 in combination with TSC-204-A0101
TSC-200-A0201 + TSC-201-B0702
Escalating doses of TSC-200-A0201 in combination with TSC-201-B0702
TSC-203-A0201 + TSC-204-A0101
Escalating doses of TSC-203-A0201 in combination with TSC-204-A0101
TSC-203-A0201 + TSC-201-B0702
Escalating doses of TSC-203-A0201 in combination with TSC-201-B0702

Locations

Country Name City State
United States University of North Carolina at Chapel Hill Chapel Hill North Carolina
United States The Cleveland Clinic Cleveland Ohio
United States Karmanos Cancer Institute Detroit Michigan
United States Memorial Healthcare System Hollywood Florida
United States Norton Cancer Institute Louisville Kentucky
United States University of Miami, Sylvester Comprehensive Cancer Center Miami Florida
United States University of Minnesota Masonic Cancer Center Minneapolis Minnesota
United States Yale Cancer Center New Haven Connecticut
United States Columbia University Herbert Irving Comprehensive Cancer Center New York New York
United States Orlando Health Orlando Florida
United States Allegheny Hospitals Network Pittsburgh Pennsylvania
United States University of Pittsburgh Medical Center Pittsburgh Pennsylvania
United States Providence Cancer Institute Franz Clinic Portland Oregon
United States HonorHealth Research and Innovation Institute Scottsdale Arizona

Sponsors (1)

Lead Sponsor Collaborator
TScan Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other To measure the persistence of T-Plex TCR-T cells in the peripheral blood with single and repeat doses Percentage of TCR-T cells in the peripheral blood after single and repeat doses Up to 24 months
Other To measure the infiltration of T-Plex TCR-T cells into tumors in post-treatment biopsies Percentage of TCR-T cells in the tumor after single and repeat doses Up to 24 months
Other To measure the immune activation markers in the tumor after single and repeated doses Status of immune activation markers in the tumor after single and repeat doses Up to 24 months
Primary Evaluate the safety of monotherapy and T- Plex combination TCR-Ts Number of subjects with dose limiting toxicities (DLT) 28 days
Primary Determine the recommended phase 2 dose of monotherapy and T- Plex combination TCR-Ts Frequency and severity of DLTs, AEs and SAEs Up to 12 months
Secondary Investigate preliminary anti-tumor activity of monotherapy and T- Plex combination TCR-Ts Response Evaluation Criteria In Solid Tumors RECIST 1.1 Up to 12 months
Secondary Investigate the feasibility of repeat dosing of monotherapy and T- Plex combination TCR-Ts Frequency and severity of DLTs, AEs and SAEs Up to 12 months
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2